Company Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S.
pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities.
The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers.
ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Country | United States |
Founded | 2004 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 624 |
CEO | Adam Grossman |
Contact Details
Address: 465 State Route 17 Ramsey, New Jersey 07446 United States | |
Phone | 201 478 5552 |
Website | admabiologics.com |
Stock Details
Ticker Symbol | ADMA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001368514 |
CUSIP Number | 000899104 |
ISIN Number | US0008991046 |
Employer ID | 56-2590442 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Adam S. Grossman | Co-Founder, President, Chief Executive Officer and Director |
Dr. Jerrold B. Grossman D.P.S., Ph.D. | Co-Founder and Vice Chairman of the Board |
Brad Tade | Chief Financial Officer and Treasurer |
Kaitlin Kestenberg | Chief Operating Officer and Senior Vice President of Compliance |
Drew Pantello | Vice President of Marketing and Corporate Development |
John Hafl | Executive Director of Sales |
Skyler Bloom | Senior Director of Business Development and Corporate Strategy |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Oct 17, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Oct 10, 2024 | 8-K | Current Report |
Oct 9, 2024 | 8-K | Current Report |
Oct 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Sep 23, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Sep 9, 2024 | 144 | Filing |
Aug 30, 2024 | 144 | Filing |
Aug 29, 2024 | 144 | Filing |
Aug 26, 2024 | 144 | Filing |
Aug 14, 2024 | 8-K | Current Report |